With approximately 3.2 million people worldwide living with end-stage renal disease, there is immense pressure on healthcare systems with long waiting lists for kidney and liver transplants
Calliditas Therapeutics has just pulled off the largest biotech IPO in Europe this year and is using it to bring a drug for a rare kidney disease to market.
Otsuka is paying $430 million for a US clinical-stage biotech company it hopes will act as a ‘drug creation engine’ to accelerate its research into kidney diseases.
Boehringer Ingelheim says it may have found the first therapy for diabetic macular ischaemia (DMI), a common and irreversible complication of the eye in people with diabet
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.